APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for the Treatment of Hepatitis C (HCV)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Analysis and Forecast 2026-2032

27 December 2025194 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antiviral Drugs for the Treatment of Hepatitis C (HCV) include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antiviral Drugs for the Treatment of Hepatitis C (HCV), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antiviral Drugs for the Treatment of Hepatitis C (HCV), also provides the sales of main regions and countries. Of the upcoming market potential for Antiviral Drugs for the Treatment of Hepatitis C (HCV), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales, projected growth trends, production technology, application and end-user industry.

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Company

AbbVie

Asegua Therapeutics

Bristol Myers Squibb

Gilead Sciences

Merck

Ascletis Pharma

Cosunter pharmaceutical

Kawin Technology

Sanhome Pharmaceutical

Beijing Sihuan Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Type

NS3/4A Protease Inhibitors

NS5A Inhibitors

NS5B Polymerase Inhibitors

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Application

Hospital and Clinic

Pharmacy

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for the Treatment of Hepatitis C (HCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for the Treatment of Hepatitis C (HCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antiviral Drugs for the Treatment of Hepatitis C (HCV) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NS3/4A Protease Inhibitors Major Manufacturers Table 3. NS5A Inhibitors Major Manufacturers Table 4. NS5B Polymerase Inhibitors Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital and Clinic Major Manufacturers Table 8. Pharmacy Major Manufacturers Table 9. Other Major Manufacturers Table 10. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends Table 11. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers Table 12. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges Table 13. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints Table 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021-2026) Table 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2027-2032) Table 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2026) & (K Units) Table 21. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032) & (K Units) Table 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021-2026) Table 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2027-2032) Table 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021-2026) Table 28. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers, Product Type & Application Table 32. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021-2026) Table 39. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2027-2032) Table 40. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 42. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 43. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021-2026) Table 44. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2027-2032) Table 45. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2026) & (US$/Unit) Table 46. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2027-2032) & (US$/Unit) Table 47. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021-2026) Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2027-2032) Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021-2026) Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2027-2032) Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2026) & (US$/Unit) Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2027-2032) & (US$/Unit) Table 59. AbbVie Company Information Table 60. AbbVie Business Overview Table 61. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 63. AbbVie Recent Development Table 64. Asegua Therapeutics Company Information Table 65. Asegua Therapeutics Business Overview Table 66. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 68. Asegua Therapeutics Recent Development Table 69. Bristol Myers Squibb Company Information Table 70. Bristol Myers Squibb Business Overview Table 71. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 73. Bristol Myers Squibb Recent Development Table 74. Gilead Sciences Company Information Table 75. Gilead Sciences Business Overview Table 76. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 78. Gilead Sciences Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 83. Merck Recent Development Table 84. Ascletis Pharma Company Information Table 85. Ascletis Pharma Business Overview Table 86. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 88. Ascletis Pharma Recent Development Table 89. Cosunter pharmaceutical Company Information Table 90. Cosunter pharmaceutical Business Overview Table 91. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 93. Cosunter pharmaceutical Recent Development Table 94. Kawin Technology Company Information Table 95. Kawin Technology Business Overview Table 96. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 98. Kawin Technology Recent Development Table 99. Sanhome Pharmaceutical Company Information Table 100. Sanhome Pharmaceutical Business Overview Table 101. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 103. Sanhome Pharmaceutical Recent Development Table 104. Beijing Sihuan Pharmaceutical Company Information Table 105. Beijing Sihuan Pharmaceutical Business Overview Table 106. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 108. Beijing Sihuan Pharmaceutical Recent Development Table 109. YiChang HEC ChangJiang Pharmaceutical Company Information Table 110. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 111. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 113. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 114. Chia Tai Tianqing Pharmaceutical Company Information Table 115. Chia Tai Tianqing Pharmaceutical Business Overview Table 116. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 118. Chia Tai Tianqing Pharmaceutical Recent Development Table 119. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 122. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 123. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2021-2026) & (US$/Unit) Table 124. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2027-2032) & (US$/Unit) Table 125. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 128. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 129. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2021-2026) & (US$/Unit) Table 130. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2027-2032) & (US$/Unit) Table 131. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 135. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 136. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032) & (K Units) Table 137. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2021-2026) & (US$/Unit) Table 138. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2027-2032) & (US$/Unit) Table 139. United States Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 140. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 141. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 142. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 145. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 146. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2021-2026) & (US$/Unit) Table 147. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2027-2032) & (US$/Unit) Table 148. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 149. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 150. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 151. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 152. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2021-2026) & (US$/Unit) Table 153. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2027-2032) & (US$/Unit) Table 154. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 156. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 157. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 158. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 159. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032) & (K Units) Table 160. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2021-2026) & (US$/Unit) Table 161. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2027-2032) & (US$/Unit) Table 162. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 163. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 164. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 165. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 166. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 167. Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 168. Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 169. Switzerland Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 170. Sweden Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 171. Poland Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 172. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 173. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 174. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 175. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 176. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2021-2026) & (US$/Unit) Table 177. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2027-2032) & (US$/Unit) Table 178. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 179. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 180. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 181. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 182. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2021-2026) & (US$/Unit) Table 183. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 187. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 188. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 193. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 194. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 201. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032) & (K Units) Table 202. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 205. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 206. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 207. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 208. Taiwan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 209. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 210. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2026) & (US$ Million) Table 211. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2027-2032) & (US$ Million) Table 212. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2026) & (K Units) Table 213. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2027-2032) & (K Units) Table 214. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2021-2026) & (US$/Unit) Table 215. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Type (2027-2032) & (US$/Unit) Table 216. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2026) & (US$ Million) Table 217. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2027-2032) & (US$ Million) Table 218. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2026) & (K Units) Table 219. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2027-2032) & (K Units) Table 220. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2021-2026) & (US$/Unit) Table 221. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Application (2027-2032) & (US$/Unit) Table 222. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 226. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 227. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032) & (K Units) Table 228. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2021-2026) & (US$/Unit) Table 229. SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Country (2027-2032) & (US$/Unit) Table 230. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 231. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 232. Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 233. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 234. Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 235. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 236. Israel Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 237. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 238. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 239. Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 240. Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List Table 244. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Image Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Share 2021 VS 2025 VS 2032 Figure 4. NS3/4A Protease Inhibitors Image Figure 5. NS5A Inhibitors Image Figure 6. NS5B Polymerase Inhibitors Image Figure 7. Other Image Figure 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital and Clinic Image Figure 11. Pharmacy Image Figure 12. Other Image Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (2021-2032) & (US$ Million) Figure 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021-2032) Figure 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (2021-2032) & (K Units) Figure 19. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales YoY (2021-2032) & (K Units) Figure 22. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales YoY (2021-2032) & (K Units) Figure 23. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales YoY (2021-2032) & (K Units) Figure 26. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021-2032) Figure 32. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021-2032) Figure 35. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021-2032) Figure 38. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021-2032) Figure 41. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Type (2021-2032) Figure 42. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Type (2021-2032) Figure 43. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Application (2021-2032) Figure 44. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Application (2021-2032) Figure 45. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Country (2021-2032) Figure 46. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Share by Country (2021-2032) Figure 47. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Type (2021-2032) Figure 48. Europe Antiviral Drugs for the Treatment

Scope & coverage.

Types
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • AbbVie
  • Asegua Therapeutics
  • Bristol Myers Squibb
  • Gilead Sciences
  • Merck
  • Ascletis Pharma
  • Cosunter pharmaceutical
  • Kawin Technology
  • Sanhome Pharmaceutical
  • Beijing Sihuan Pharmaceutical
  • YiChang HEC ChangJiang Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Type
  3. 1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NS3/4A Protease Inhibitors
  5. 1.2.3 NS5A Inhibitors
  6. 1.2.4 NS5B Polymerase Inhibitors
  7. 1.2.5 Other
  8. 1.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Application
  9. 1.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital and Clinic
  11. 1.3.3 Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Dynamics
  1. 2.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends
  2. 2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers
  3. 2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region
  3. 3.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2021-2026)
  5. 3.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Region (2027-2032)
  6. 3.2.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region
  9. 3.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2026)
  11. 3.4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032)
  12. 3.4.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Manufacturers
  2. 4.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Manufacturers
  6. 4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers, Product Type & Application
  13. 4.7 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market CR5 and HHI
  16. 4.8.2 2025 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Tier 1, Tier 2, and Tier 3
5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Type
  1. 5.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type
  2. 5.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type
  6. 5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type
6 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Application
  1. 6.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application
  2. 6.1.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application
  6. 6.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application
7 Company Profiles
  1. 7.1 AbbVie
  2. 7.1.1 AbbVie Company Information
  3. 7.1.2 AbbVie Business Overview
  4. 7.1.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  6. 7.1.5 AbbVie Recent Developments
  7. 7.2 Asegua Therapeutics
  8. 7.2.1 Asegua Therapeutics Company Information
  9. 7.2.2 Asegua Therapeutics Business Overview
  10. 7.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  12. 7.2.5 Asegua Therapeutics Recent Developments
  13. 7.3 Bristol Myers Squibb
  14. 7.3.1 Bristol Myers Squibb Company Information
  15. 7.3.2 Bristol Myers Squibb Business Overview
  16. 7.3.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  18. 7.3.5 Bristol Myers Squibb Recent Developments
  19. 7.4 Gilead Sciences
  20. 7.4.1 Gilead Sciences Company Information
  21. 7.4.2 Gilead Sciences Business Overview
  22. 7.4.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  24. 7.4.5 Gilead Sciences Recent Developments
  25. 7.5 Merck
  26. 7.5.1 Merck Company Information
  27. 7.5.2 Merck Business Overview
  28. 7.5.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  30. 7.5.5 Merck Recent Developments
  31. 7.6 Ascletis Pharma
  32. 7.6.1 Ascletis Pharma Company Information
  33. 7.6.2 Ascletis Pharma Business Overview
  34. 7.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  36. 7.6.5 Ascletis Pharma Recent Developments
  37. 7.7 Cosunter pharmaceutical
  38. 7.7.1 Cosunter pharmaceutical Company Information
  39. 7.7.2 Cosunter pharmaceutical Business Overview
  40. 7.7.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  42. 7.7.5 Cosunter pharmaceutical Recent Developments
  43. 7.8 Kawin Technology
  44. 7.8.1 Kawin Technology Company Information
  45. 7.8.2 Kawin Technology Business Overview
  46. 7.8.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  48. 7.8.5 Kawin Technology Recent Developments
  49. 7.9 Sanhome Pharmaceutical
  50. 7.9.1 Sanhome Pharmaceutical Company Information
  51. 7.9.2 Sanhome Pharmaceutical Business Overview
  52. 7.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  54. 7.9.5 Sanhome Pharmaceutical Recent Developments
  55. 7.10 Beijing Sihuan Pharmaceutical
  56. 7.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 7.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 7.10.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  60. 7.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 7.11 YiChang HEC ChangJiang Pharmaceutical
  62. 7.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  63. 7.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  64. 7.11.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  66. 7.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
  67. 7.12 Chia Tai Tianqing Pharmaceutical
  68. 7.12.1 Chia Tai Tianqing Pharmaceutical Company Information
  69. 7.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
  70. 7.12.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  72. 7.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  2. 8.1.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032)
  3. 8.1.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032)
  4. 8.1.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2032)
  5. 8.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 8.2.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032)
  7. 8.2.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032)
  8. 8.2.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2032)
  9. 8.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  10. 8.3.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  2. 9.1.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032)
  4. 9.1.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2032)
  5. 9.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 9.2.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032)
  8. 9.2.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2032)
  9. 9.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  10. 9.3.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  2. 10.1.1 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032)
  3. 10.1.2 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032)
  4. 10.1.3 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2032)
  5. 10.2 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 10.2.1 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032)
  7. 10.2.2 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032)
  8. 10.2.3 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  2. 11.1.1 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032)
  4. 11.1.3 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2032)
  5. 11.2 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 11.2.1 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032)
  8. 11.2.3 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2032)
  9. 11.3 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  10. 11.3.1 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Type
  2. 12.1.1 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Type (2021-2032)
  5. 12.2 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Application
  6. 12.2.1 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Application (2021-2032)
  9. 12.3 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Size by Country
  10. 12.3.1 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain Analysis
  2. 13.1.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Production Mode & Process
  6. 13.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors
  9. 13.2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst